30 closest matches · ranked by relevance
HIV · Sexually Transmitted Diseases · HIV Infections
Primary: Number of Sexual Partners, 3 Months Post Intervention — 2.19; 2.04; 2.14; 2.13 number of partners
Gonorrhea · Chlamydia
Primary: GC/CT Detection Rates — 15.2; 12.1; 11 No. of patients with positive GC/CT
Self Efficacy · HIV Prevention · STI Prevention
Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04
Uterine Cervical Neoplasms · Sexually Transmitted Diseases
Primary: Concordance Between Vaginal Self-swab Results and Provider-collected Cervical Swab Results for HPV DNA Among Sexually Active FTM Adults — 15; 2; 6; 108 Participants…
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Number of Participants That Schedule a Pre-test Session — 74 Participants
Sexually Transmitted Infection
Primary: Doxycycline Concentration in Rectal Tissue — 2.330 µg/g
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Exposure to Sexually Transmissible Disorder (Event)
Primary: Feasibility as Assessed by the Number of Participants Who Are Enrolled With a Partner — 17; 17 Participants
Teen Sexual Health
Primary: Dual Protection Behaviors, Reported in Surveys and Reviewed in the Medical Record. — 7; 6; 8; 8 Participants
HIV Infections · Sexually Transmitted Diseases
Primary: Efficacy of Internet-based Program for Increasing Condom Use With Non-main Sex Partners — .68; .56 percentage of sex acts protected by cond
Gonorrhea · Chlamydia · Syphilis
Primary: Number of Quarterly Visits In Which an STI Was Detected — 61; 82; 36; 39 No. quarterly visits with STI event
Neisseria Gonorrhoeae Infection · Chlamydia Trachomatis Infection
Primary: Incidence Rate of Ng Plus Ct Detected at Any Site Whilst Individuals Are Screened vs. Not Screened — 0.155; 0.205 Ng or CT cases per study visit
Human Papillomavirus Infection
Primary: HPV Incidence Rates, Expressed as Incident Infections/1000 Infection-months at Risk. These Were Calculated Separately for Females and Males Across the Four Vaccine…
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
HIV/AIDS · Health Knowledge, Attitudes, Practice · STI
Primary: Self-reported HIV or STI Testing in Past 3 Months — 76; 88 Participants — p=0.914
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Gonococcal Infection
Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000
Gonococcal Infection
Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053
Human Immunodeficiency Virus
Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD
HIV Infections · Schizophrenia · Schizoaffective Disorder
Primary: Change in Immunization Status — 73; 4 participants — p=<0.001
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Syphilis
Primary: Syphilis Tests Undertaken — 29; 37 Participants
Urethritis
Primary: Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea — 3; 4; 0; 4 Participants
HIV Infections · HIV/AIDS · Neisseria Gonorrheae Infection
Primary: Incidence of N. Gonorrhoeae, C. Trachomatis, or Early Syphilis Infection by Laboratory-based Diagnosis — 25.1; 29.0 Events per 100 person-years
Sexually Transmitted Infection · Alcohol Use Complicating the Puerperium · Alcohol Use Complicating Pregnancy, Unspecified Trimester
Primary: Unprotected Sexual Occasions (USOs) — 27.73; 41.50; 8.68; 14.70 USOs per participant — p=0.2964